Pulike Biological Engineering, Inc. (SHA:603566)
China
· Delayed Price · Currency is CNY 14.21
+0.30 (2.16%)
Jul 14, 2025, 2:45 PM CST
SHA:603566 Revenue
Pulike Biological Engineering had revenue of 278.62M CNY in the quarter ending March 31, 2025, with 18.32% growth. This brings the company's revenue in the last twelve months to 1.09B, down -8.09% year-over-year. In the year 2024, Pulike Biological Engineering had annual revenue of 1.04B, down -16.77%.
Revenue (ttm)
1.09B
Revenue Growth
-8.09%
P/S Ratio
4.47
Revenue / Employee
699.99K
Employees
1,551
Market Cap
4.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.04B | -210.13M | -16.77% |
| Dec 31, 2023 | 1.25B | 22.62M | 1.84% |
| Dec 31, 2022 | 1.23B | 131.50M | 11.97% |
| Dec 31, 2021 | 1.10B | 170.06M | 18.31% |
| Dec 31, 2020 | 928.51M | 265.32M | 40.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |